



## LIQUID BIOPSY PROTEINS AS PSC-SPECIFIC AND PAN-CCA BIOMARKERS OF CANCER RISK, EARLY DIAGNOSIS AND SURVIVAL MIRRORING TUMOR CELLS

Ainhoa Lapitz<sup>1</sup>, Mikel Azkargorta<sup>2,3</sup>, Piotr Milkiewicz<sup>4,5</sup>, Paula Olaizola<sup>1</sup>, Ekaterina Zhuravleva<sup>6</sup>, Marit M. Grimsrud<sup>7</sup>, Christoph Schramm<sup>8,9,10</sup>, Ander Arbelaiz<sup>1</sup>, Colm J. O'Rourke<sup>6</sup>, Adelaida La Casta<sup>1</sup>, Malgorzata Milkiewicz<sup>12</sup>, Tania Pastor<sup>1</sup>, Mette Vesterhus<sup>7,11</sup>, Raul Jiménez-Agüero<sup>1</sup>, Michael T. Dill<sup>13,14</sup>, Angela Lamarca<sup>15</sup>, Juan W. Valle<sup>15</sup>, Rocio I.R. Macias<sup>3,16</sup>, Laura Izquierdo-Sánchez<sup>1</sup>, Ylenia Pérez Castaño<sup>1,17</sup>, Francisco Javier Caballero-Camino<sup>1</sup>, Ioana Riano<sup>1</sup>, Marcin Krawczyk<sup>18,19</sup>, Cesar Ibarra<sup>20</sup>, Javier Bustamante<sup>20</sup>, Luiz Miguel Nova-Camacho<sup>21</sup>, Juan M. Falcon-Pérez<sup>3,22,23</sup>, Felix Elortza<sup>2,3</sup>, Maria J. Perugorria<sup>1,3,24</sup>, Jesper B. Andersen<sup>6</sup>, Luis Bujanda<sup>1,3</sup>, Tom H. Karlsen<sup>7</sup>, Trine Folseraas<sup>7,25</sup>, Pedro M. Rodrigues<sup>1,3,23</sup> and Jesus M. Banales<sup>1,3,23,26</sup>

<sup>1</sup>Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute-Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastian. <sup>2</sup>Proteomics Platform, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), ProteoRed-ISCIII, Bizkaia Science and Technology Park, Derio. <sup>3</sup>National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd), ISCIII, Madrid. <sup>4</sup>Liver and Internal Medicine Unit, Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Poland. <sup>5</sup>Translational Medicine Group, Pomeranian Medical University, Szczecin, Poland. <sup>6</sup>Biotech Research and Innovation Centre, Department of Health and Medical Sciences, University of Copenhagen, Denmark. <sup>7</sup>Norwegian PSC Research Center, Department of Transplantation Medicine, Division of Surgery, Inflammatory Medicine and Transplantation, Oslo University Hospital, Rikshospitalet, Oslo, Norway. <sup>8</sup>European Reference Network Hepatological Diseases (ERN RARE-LIVER), Hamburg, Germany. <sup>9</sup>1<sup>st</sup> Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. <sup>10</sup>Martin Zeitz Centre for Rare Diseases, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany. <sup>11</sup>Department of Clinical Science, University of Bergen, Bergen, Norway. <sup>12</sup>Department of Medical Biology, Pomeranian Medical University in Szczecin, Poland. <sup>13</sup>Department of Gastroenterology, Infectious Diseases and Intoxication, Heidelberg University Hospital, Heidelberg, Germany. <sup>14</sup>Experimental Hepatology, Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany. <sup>15</sup>Department of Medical Oncology, The Christie NHS Foundation Trust/Division of Cancer Sciences, University of Manchester, Manchester, UK. <sup>16</sup>Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, Biomedical Research Institute of Salamanca (IBSAL), Salamanca. <sup>17</sup>Osakidetza Basque Health Service, Bidasoa IHO, Bidasoa Hospital, Department of Digestive System, Irun. <sup>18</sup>Department of Medicine II, Saarland University Medical Centre, Saarland University, Homburg, Germany. <sup>19</sup>Laboratory of Metabolic Liver Diseases, Centre for Preclinical Research, Department of General, Transplant and Liver Surgery, Warsaw, Poland. <sup>20</sup>Osakidetza Basque Health Service, Ezkerraldea-Enkarterri-Cruces IHO, Cruces University Hospital, Barakaldo. <sup>21</sup>Osakidetza Basque Health Service, Donostialdea IHO, Donostia University Hospital, Department of Pathology, San Sebastian. <sup>22</sup>Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Exosomes Laboratory, Derio. <sup>23</sup>Ikerbasque, Basque Foundation for Science, Bilbao. <sup>24</sup>Department of Medicine, Faculty of Medicine and Nursing, University of the Basque Country, UPV/EHU, Leioa. <sup>25</sup>Section of Gastroenterology, Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway. <sup>26</sup>Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona.

## Resumen

**Introduction and objectives:** Cholangiocarcinomas (CCAs), heterogeneous biliary tumors with

dismal prognosis, lack accurate early-diagnostic methods, especially important for individuals at high-risk (i.e., primary sclerosing cholangitis (PSC)). Here, we searched for protein biomarkers in serum extracellular vesicles (EVs).

**Methods:** EVs from patients with isolated PSC (n = 45), concomitant PSC-CCA (n = 42), PSC who developed CCA during follow-up (PSC to CCA; n = 25), CCAs from non-PSC etiology (n = 56), hepatocellular carcinoma (n = 34) and healthy individuals (n = 55) were characterized by mass-spectrometry. Diagnostic biomarkers of PSC-CCA, non-PSC CCA or CCAs regardless etiology (pan-CCAs) were defined, and their expression was evaluated in human organs/tissues and within CCA tumors at single-cell level. Prognostic EV-biomarkers for CCA were investigated.

**Results:** High-throughput proteomics identified candidate diagnostic biomarkers for PSC-CCA, non-PSC CCA or pan-CCA, as well as and for differential diagnosis of intrahepatic CCA and HCC, that were cross-validated by ELISA using total serum. Machine learning logit modelling disclosed CRP/FRIL/Fibrinogen algorithm with diagnostic value for early-stage PSC-CCA v s isolated PSC (AUC = 0.944; OR = 82.0), overpowering CA19-9 (AUC = 0.735; OR = 9.3). An algorithm combining CRP/VWF/PIGR//Fibrinogen allowed the diagnosis of early-stage non-PSC CCAs compared to healthy individuals (AUC = 0.999; OR = 1,115). Noteworthy, levels of Fibrinogen/CRP/PIGR/FRIL showed predictive capacity for CCA development in patients with PSC before clinical evidences of malignancy. Multi-organ transcriptomic analysis revealed that serum EVbiomarkers were mostly expressed in hepatobiliary tissues, and scRNA-seq and immunofluorescence analysis of CCA tumors showed their presence mainly in malignant cholangiocytes. Multivariable analysis unveiled EV-prognostic biomarkers independent to clinical features, with COMP/GNAI2/CFAI and ACTN1/MYCT1/PF4V associated negatively or positively to patients' survival, respectively.

**Conclusions:** Serum EVs contain protein biomarkers for the prediction, early diagnosis and prognosis estimation of CCA, representing a novel tumor cell-derived liquid biopsy for personalized medicine.